Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (Nasdaq: RNAC) is a late clinical-stage biotechnology company developing mRNA-modified cell therapies for autoimmune diseases. Its autologous CAR-T candidates are made by collecting a patient’s cells, expanding them, and introducing mRNA that encodes a therapeutic receptor; the lead… From the company’s description.
Over the twelve months to Sep 30, 2026, Cartesian Therapeutics, Inc. reported revenue of $1.02M, down 6.0% from a year earlier, and a net loss of $127.46M. Operations used $88.66M in cash. In fiscal 2025, it reported revenue of $2.80M, down 92.8% from fiscal 2024, and a net loss of $130.30M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cartesian Therapeutics, Inc. does
In the company’s own words
Cartesian Therapeutics, Inc. (Nasdaq: RNAC) is a late clinical-stage biotechnology company developing mRNA-modified cell therapies for autoimmune diseases. Its autologous CAR-T candidates are made by collecting a patient’s cells, expanding them, and introducing mRNA that encodes a therapeutic receptor; the lead candidate, Descartes-08, targets BCMA and is in development for generalized myasthenia gravis and myositis. The company’s approach is designed for repeated outpatient infusions without preconditioning chemotherapy, and its potential customers are patients and healthcare providers, subject to regulatory approval. Cartesian also initiated a pediatric trial of Descartes-08 for juvenile dermatomyositis; it discontinued development in systemic lupus erythematosus and paused Descartes-15, a next-generation candidate studied in multiple myeloma. The company manufactures Descartes-08 at its wholly owned cGMP facility in Frederick, Maryland, and reports no operating segments. Its current business follows the 2023 merger of Selecta Biosciences and Old Cartesian, after which Selecta changed its name to Cartesian Therapeutics. As of December 31, 2025, it had administered Descartes-08 to more than 100 patients across studies. Its website is www.cartesiantherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FREDERICK, MD
- Fiscal year end
- December
- CIK
- 1453687
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cartesian Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cartesian Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cartesian Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cartesian Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cartesian Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”